Serimmune is an immune intelligence company focused on identifying and exploiting the universe of relationships between antibodies and antigens. Our proprietary technology (SERA) provides a holistic view of the circulating antibody repertoire to identify diverse immunogenic factors in disease and health. Serimmune’s human immunity map is a growing database that can be interrogated to fuel the development of multiplex diagnostics, vaccines, and therapeutics. Serimune is in Santa Barbara, CA with strong ties to University of California Santa Barbara where the SERA technology was originally developed.

Press Ganey, the leading Human Experience (HX) healthcare performance improvement company, offers an integrated suite of solutions that address safety, clinical excellence, patient experience and workforce engagement. The company works with more than 41,000 healthcare facilities in its mission to reduce patient suffering and enhance caregiver resilience to improve the overall safety, quality and experience of care. Press Ganey is a PG Forsta company.

Nona Biosciences specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection.

MedQIA, WorldCare Clinical and DARC, have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s unique AI-based software platform integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data.

BDD has world leading expertise in the development and clinical testing of innovative pharmaceutical products. Our development strategies are underpinned by our understanding of biopharmaceutics which has evolved over years of experience in visualising in vivo performance of products using gamma scintigraphy. BDD combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. To learn more, please visit https://www.bddpharma.com/

Clinical Outcomes Solution is a global health economics and outcomes research consulting group providing 360° support and services across all facets of clinical outcomes research to assist with data-driven decisions for informing patient care. www.clinoutsolutions.com

Biond Biologics is a private, clinical-stage biotech company, developing a pioneering intracellular drug delivery platform called INspire and innovative Immuno-oncology therapies. INspire, delivers biologics, e.g., nanobodies and proteins for intracellular targets considered hard-to-target such as the RAF, RAS proteins. Our IO pipeline includes three novel biological drugs, BND-22 an anti ILT2/LILRB1 antibody, licensed to Sanofi and is in phase 1; BND-35 an anti ILT3/LILRB4, with phase 1 initiating in H1 2024 and BND-67 - A nanobody based agent targeting CD28 shedding potentially effecting resistance to anti-PD-1 therapy.

Virogin Biotech is a clinical-stage immuno-oncology company, with a primary focus on innovative HSV-1 based oncolytic virus (OV) and mRNA-based (including self-amplifying RNA/saRNA) therapeutics to elicit robust and durable anti-tumor immune response against solid tumors. Both the platforms exhibit a high degree of complementarity via a mechanism of heterologous prime-boost. Enhanced anti-tumor efficacy has been observed if OV and mRNA tumor vaccines were combined due to (1) modulation of immune-suppressive tumor microenvironment through release of immunological payloads carried by OV, and (2) antigen spread via direct tumor cell lysis triggered by OV infection, which functions like an in situ personalized tumor vaccine. Yet each platform has ‘plug-to-play' features to independently develop novel therapies against cancer & other indications. Our oncolytic HSV-1 platform has two candidates in clinical trials, with our most advanced asset in Phase 2. Candidates from our mRNA platform have also completed preclinical proof of concept.

Saros Therapeutics is a private, pre-clinical biotech company developing therapies that enhance the immune response against cancer by targeting STING. The technology was engineered to overcome problems of prior STING therapies through cell specific targeting, increased potency and a better route of administration. Successful development of Saros' lead program will bring tremendous benefits to patients with many different types of cancer.

Cytek® Biosciences is a leading cell analysis solutions company advancing the next generation of tools with patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s portfolio includes the Cytek Aurora™, Cytek Aurora™ CS and Cytek Northern Lights™ systems, Amnis® and Guava® products, reagents, software, and services to provide comprehensive solutions for customers.

Prokarium is a clinical-stage biopharmaceutical company bioengineering Living Cures through advanced synthetic biology. Our lead program, progressing through US clinical trials for bladder cancer, introduces a single-dose therapy redesigning the treatment paradigm for patients. Prokarium's innovative Living Cures platform aims to transform precision medicine with off-the-shelf programmable therapeutics, establishing a new class of immunotherapies.

Founded in 2023, Kincell Bio’s mission is to be a trusted manufacturing services partner for early-stage cell therapy companies by providing access to CMC development and clinical manufacturing services for emerging leaders in cell therapy. 

Headquartered in Gainesville, Florida, Kincell is a technology-forward contract development and manufacturing organization (CDMO) dedicated to streamline analytical development, process development, CMC consulting and early-stage GMP cell therapy manufacturing. Kincell’s primary focus is to aggregate technology, experiences and ambitions to manufacture commercially viable immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK and CAR-M programs.